Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma

Inclusion Criteria:

All Parts (key criteria)

• Hematologic: Absolute neutrophil count ≥1.5×10⁹/L, platelets ≥100×10⁹/L, hemoglobin ≥9 g/dL

• Hepatic: Bilirubin ≤1.5× upper limits of normal (ULN), ALT and AST ≤2.5×ULN; in caseof liver involvement: AST and ALT ≤5×ULN

• Renal: Creatinine clearance ≥60 mL/min calculated by Cockcroft-Gault formula

• Prothrombin time/international normalized ratio (INR) ≤1.5×ULN

• Albumin ≥3.0 mg/dL

• Proteinuria <1 g/24 hours

• Eastern Cooperative Oncology Group (ECOG) performance status ≤1

• Estimated life expectancy ≥3 months as per investigator's assessment

• A female patient is eligible to participate if she is not pregnant, notbreastfeeding, not of childbearing potential/ agreed with contraception

Part A

• Patient has advanced inoperable or metastatic disease

• Patient has no better treatment option available

• Measurable or non-measurable disease according to RECIST 1.1

• Histological or cytological evidence of adenocarcinoma of pancreas that is advancedor metastatic

Part B (in addition to relevant A criteria)*Histological or cytological evidence of adenocarcinoma of the pancreas that is advanced or metastatic (pancreas)

Part C (in addition to relevant A criteria)*Must have received at least one prior systemic therapy for advanced or metastatic disease (pancreas)

Part D (in addition to relevant B criteria)*Histological or cytological evidence of adenocarcinoma of the pancreas that is advanced inoperable or metastatic (pancreas)

Exclusion Criteria:

All Parts (key criteria)

• Patient has received radiation therapy ≤14 days before day 1 of cycle 1 or has notrecovered to grade ≤1 from treatment-related side effects

• Severe preexisting medical conditions as per judgement of the investigator (e.g.,active gastric or GEJ ulcer with or without bleeding, complete or incomplete gastricoutlet syndrome with persistent or repetitive bleeding)

• History of interstitial pneumonitis or pulmonary fibrosis

• Symptomatic central nervous system malignancy. Patients with asymptomatic or treatedcentral nervous system metastases may be eligible if they are not treated withcorticosteroids or anticonvulsants and the disease is stable for at least 60 days.

• Patient has peripheral sensory neuropathy grade ≥2

• Active infection requiring systemic therapy within ≤7 days prior to day 1 of cycle 1

• History of major ventricular arrhythmias (e.g., ventricular tachycardia, ventricularfibrillation, Torsades de Pointes)

• Bradycardia (<50 beats per minute)

• Family history of sudden cardiac death before age 50

• History or family history of congenital long QT syndrome

• Major surgical intervention ≤28 days prior to ICF signature or incomplete woundhealing after surgical intervention

• Time since last transfusion of RBCs ≤14 days before cycle 1 day 1

• Vaccination with a live or live-attenuated vaccine within 30 days prior the firstdose of trial interventions

Part B/D (key)

*Patients with contraindications to any component of the first-line SoC treatment